Core Points - XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing therapies for progressive kidney disease [1] - Institutional Shareholder Services Inc. (ISS) has recommended that shareholders vote "FOR" all proposed resolutions at the upcoming Annual and Special Meeting on September 12, 2024 [1][2] - The Board of Directors of XORTX also recommends shareholders vote "FOR" all proposed items [2] Meeting Details - The Annual and Special Meeting of Shareholders will take place on September 12, 2024, at 10:00 am (Calgary Time) at the company's offices [2] - The proxy voting deadline is set for 10:00 am (Calgary time) on September 10, 2024 [2] Company Overview - XORTX has two clinically advanced products: XRx008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD) and XRx-101 for acute kidney injury related to COVID-19 [4] - The company is also developing XRx-225, a pre-clinical program for Type 2 Diabetic Nephropathy [4] - XORTX aims to improve patient quality of life by targeting purine metabolism and inhibiting uric acid production [4]
Independent Proxy Advisory Firm ISS Recommends XORTX Shareholders Vote FOR ALL Proposed Items at the Upcoming Annual and Special Meeting of Shareholders